No Data
No Data
Immutep Ltd Announces Cessation of Performance Rights
Immutep's Phase 1 Trial Shows Favorable Safety Profile of Drug Candidate for Autoimmune Disease; Shares Down 3%
Immutep Dips as Safety Test for Flagship Drug IMP761 Shows No Adverse Effects
Immutep Ltd Reveals Key LAG-3 Binding Discovery
Immutep Says Phase 2B Trial of Head, Neck Cancer Combination Therapy Shows 'Strong' Overall Survival; Shares Up 3%
ASX 300 Healthcare Stock Lifts off on Promising New Results